These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30782385)

  • 1. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    Kogure Y; Ishii Y; Oki M
    J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
    [No Abstract]   [Full Text] [Related]  

  • 2. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
    Wang H; Zhang L; Liu W
    J Thorac Oncol; 2019 Jul; 14(7):e141-e143. PubMed ID: 31235036
    [No Abstract]   [Full Text] [Related]  

  • 3. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    Hsu CL; Chen KY; Kuo SW; Chang YL
    J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
    Peng TR; Wu TW
    Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
    [No Abstract]   [Full Text] [Related]  

  • 5. Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.
    Freitas C; Sampaio L; Fernandes G
    J Neurooncol; 2019 Nov; 145(2):399-402. PubMed ID: 31506753
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
    Romeo MAL; Garassino MC; Moiola L; Galli G; Comi G; Martinelli V; Filippi M
    J Neurol; 2019 Dec; 266(12):3163-3166. PubMed ID: 31586260
    [No Abstract]   [Full Text] [Related]  

  • 7. Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event.
    Thakker M; Quadri K; Desai A; Illyas W; Kim MY; Desai S; Rager C
    J Oncol Pract; 2019 Nov; 15(11):613-614. PubMed ID: 31580769
    [No Abstract]   [Full Text] [Related]  

  • 8. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
    Tamura T; Akimoto E; Matsumoto C; Mori S; Nishi T; Kudo K; Kuyama S
    J Thorac Oncol; 2018 Oct; 13(10):1606-1607. PubMed ID: 29730378
    [No Abstract]   [Full Text] [Related]  

  • 9. Susac's syndrome as an immune-related adverse event after pembrolizumab: a case report.
    De Groot M; Compter A; De Langen AJ; Brandsma D
    J Neurol; 2020 Jan; 267(1):282-284. PubMed ID: 31701330
    [No Abstract]   [Full Text] [Related]  

  • 10. Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.
    Umeguchi H; Takenoshita H; Inoue H; Kurihara Y; Sakaguchi C; Yano S; Hasuzawa N; Sakamoto S; Sakamoto R; Ashida K
    J Oncol Pract; 2018 Jul; 14(7):449-451. PubMed ID: 29906213
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.
    Jo H; Yoshida T; Horinouchi H; Yagishita S; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Yamamoto N; Takahashi K; Motoi N; Ohe Y
    Cancer Immunol Immunother; 2022 Feb; 71(2):387-398. PubMed ID: 34180007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
    J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab.
    Hirabae A; Ichihara E; Sunami R; Ota M; Iwamoto Y; Maeda Y; Kiura K
    Acta Med Okayama; 2020 Oct; 74(5):423-425. PubMed ID: 33106698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An unknown reaction to pembrolizumab: giant cell arteritis.
    Micaily I; Chernoff M
    Ann Oncol; 2017 Oct; 28(10):2621-2622. PubMed ID: 28633343
    [No Abstract]   [Full Text] [Related]  

  • 15. Prurigo nodularis and pembrolizumab: A therapeutic challenge.
    Fattore D; Panariello L; Annunziata MC; Fabbrocini G
    Eur J Cancer; 2019 Mar; 110():8-10. PubMed ID: 30735833
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytokine Release Syndrome Resulting From Anti-Programmed Death-1 Antibody: Raising Awareness Among Community Oncologists.
    Adashek ML; Feldman M
    J Oncol Pract; 2019 Sep; 15(9):502-504. PubMed ID: 31310573
    [No Abstract]   [Full Text] [Related]  

  • 17. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
    [No Abstract]   [Full Text] [Related]  

  • 18. A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
    Higashiyama RI; Yoshida T
    J Thorac Oncol; 2024 Sep; 19(9):e33-e34. PubMed ID: 39242142
    [No Abstract]   [Full Text] [Related]  

  • 19. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
    Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
    Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.